The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor

Biochemical Pharmacology

Volumn 83, Issue 4, 2012, Pages 472-479

  Mosi, Renee M ^a   Anastassova, Virginia ^a   Cox, Jennifer ^a   Darkes, Marilyn C ^a   Idzan, Stefan R ^a   Labrecque, Jean ^a   Lau, Gloria ^a   Nelson, Kim L ^a   Patel, Ketan ^a   Santucci, Zefferino ^a   Wong, Rebecca S Y ^a   Skerlj, Renato T ^a   Bridger, Gary J ^a   Huskens, Dana ^b   Schols, Dominique ^b   Fricker, Simon P ^a  

^a GENZYME CORPORATION   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Allosteric; AMD11070; Chemokine receptor; CXCR4; HIV

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE TRIPHOSPHATE; PROTEIN INHIBITOR; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; STROMAL CELL DERIVED FACTOR 1BETA;

ALLOSTERISM; ARTICLE; BINDING ASSAY; CALCIUM TRANSPORT; CELL LINE; CHEMOTAXIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS REPLICATION;

ADMINISTRATION, ORAL; AMINOQUINOLINES; ANIMALS; ANTI-HIV AGENTS; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; CELL LINE; CHEMOKINE CXCL12; DOGS; GENE EXPRESSION REGULATION; HIV-1; HUMANS; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84855769525     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.11.020     Document Type: Article

References (53)

1. P.A. Volberding, and S.G. Deeks Antiretroviral therapy and management of HIV infection Lancet 376 2010 49 62
2. E. Poveda, V. Briz, and V. Soriano Enfuvirtide, the first fusion inhibitor to treat HIV infection AIDS Rev 7 2005 139 147 (Pubitemid 41671913)
3. J.P. Moore, and R.W. Doms The entry of entry inhibitors: a fusion of science and medicine Proc Natl Acad Sci USA 100 2003 10598 10602 (Pubitemid 37140074)
4. B.J. Doranz, J.F. Berson, J. Rucker, and R.W. Doms Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1) Immunol Res 16 1997 15 28 (Pubitemid 27129627)
5. M. Baggiolini Chemokines and leukocyte traffic Nature 392 1998 565 568 (Pubitemid 28207705)
6. A. Zlotnik, and O. Yoshie Chemokines: a new classification system and their role in immunity Immunity 12 2000 121 127 (Pubitemid 30398626)
7. C. Seibert, and T.P. Sakmar Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs Curr Pharm Des 10 2004 2041 2062 (Pubitemid 38842648)
8. R.M. Gulick, J. Lalezari, J. Goodrich, N. Clumeck, E. DeJesus, and A. Horban Maraviroc for previously treated patients with R5 HIV-1 infection N Engl J Med 359 2008 1429 1441
9. C.M. Perry Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection Drugs 70 2010 1189 1213
10. S. Sayana, and H. Khanlou Maraviroc: a new CCR5 antagonist Expert Rev Anti Infect Ther 7 2009 9 19
11. D.A. Cooper, J. Heera, J. Goodrich, M. Tawadrous, M. Saag, and E. Dejesus Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection J Infect Dis 201 2010 803 813
12. W. Kromdijk, A.D. Huitema, and J.W. Mulder Treatment of HIV infection with the CCR5 antagonist maraviroc Expert Opin Pharmacother 11 2010 1215 1223
13. S.P. Fricker, V. Anastassov, J. Cox, M.C. Darkes, O. Grujic, and S.R. Idzan Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4 Biochem Pharmacol 72 2006 588 596 (Pubitemid 44163295)
14. S. Hatse, K. Princen, G. Bridger, E. De Clercq, and D. Schols Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4 FEBS lett 527 2002 255 262 (Pubitemid 35253875)
15. D. Schols, J.A. Este, G. Henson, and E. De Clercq Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4 Antiviral Res 35 1997 147 156 (Pubitemid 27351415)
16. G.A. Donzella, D. Schols, S.W. Lin, J.A. Este, K.A. Nagashima, and P.J. Maddon AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor Nat Med 4 1998 72 77 (Pubitemid 28133082)
17. D. Schols, S. Struyf, J. Van Damme, J.A. Este, G. Henson, and E. De Clercq Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4 J Exp Med 186 1997 1383 1388 (Pubitemid 27469034)
18. C.W. Hendrix, A.C. Collier, M.M. Lederman, D. Schols, R.B. Pollard, and S. Brown Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection J Acquir Immune Defic Syndr 37 2004 1253 1262 (Pubitemid 39281506)
19. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma J Clin Oncol 22 2004 1095 1102 (Pubitemid 41095043)
20. W.C. Liles, H.E. Broxmeyer, E. Rodger, B. Wood, K. Hubel, and S. Cooper Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist Blood 102 2003 2728 2730 (Pubitemid 37248839)
21. H.E. Broxmeyer, C.M. Orschell, D.W. Clapp, G. Hangoc, S. Cooper, and P.A. Plett Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist J Exp Med 201 2005 1307 1318 (Pubitemid 40629073)
22. + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data Bone Marrow Transplant 41 2008 331 338 (Pubitemid 351330727)
23. N. Flomenberg, S.M. Devine, J.F. Dipersio, J.L. Liesveld, J.M. McCarty, and S.D. Rowley The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone Blood 106 2005 1867 1874 (Pubitemid 41208607)
24. J.F. DiPersio, I.N. Micallef, P.J. Stiff, B.J. Bolwell, R.T. Maziarz, and E. Jacobsen Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma J Clin Oncol 27 2009 4767 4773
25. J.F. DiPersio, E.A. Stadtmauer, A. Nademanee, I.N. Micallef, P.J. Stiff, and J.L. Kaufman Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma Blood 113 2009 5720 5726
26. G. Calandra, G. Bridger, and S. Fricker CXCR4 in clinical hematology Curr Top Microbiol Immunol 341 2010 173 191
27. R.T. Skerlj, G.J. Bridger, A. Kaller, E.J. McEachern, J.B. Crawford, and Y. Zhou Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication J Med Chem 53 2010 3376 3388
28. N.D. Stone, S.B. Dunaway, C. Flexner, C. Tierney, G.B. Calandra, and S. Becker Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects Antimicrob Agents Chemother 51 2007 2351 2358 (Pubitemid 47047310)
29. G. Moyle, E. DeJesus, M. Boffito, R.S. Wong, C. Gibney, and K. Badel Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1 Clin Infect Dis 48 2009 798 805
30. E. De Clercq, N. Yamamoto, R. Pauwels, J. Balzarini, M. Witvrouw, and K. De Vreese Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 Antimicrob Agents Chemother 38 1994 668 674 (Pubitemid 24113999)
31. R.S. Wong, V. Bodart, M. Metz, J. Labrecque, G. Bridger, and S.P. Fricker Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors Mol Pharmacol 74 2008 1485 1495
32. V. Bodart, V. Anastassov, M.C. Darkes, S.R. Idzan, J. Labrecque, and G. Lau Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4 Biochem Pharmacol 78 2009 993 1000
33. J. Labrecque, V. Anastassov, G. Lau, M. Darkes, R. Mosi, and S.P. Fricker The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5 Assay Drug Dev Technol 3 2005 637 648 (Pubitemid 43256955)
34. M.P. Crump, J.H. Gong, P. Loetscher, K. Rajarathnam, A. Amara, and F. Arenzana-Seisdedos Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1 EMBO J 16 1997 6996 7007 (Pubitemid 27520800)
35. P.A. Hernandez, R.J. Gorlin, J.N. Lukens, S. Taniuchi, J. Bohinjec, and F. Francois Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease Nat Genet 34 2003 70 74 (Pubitemid 36548793)
36. T. Kawai, and H.L. Malech WHIM syndrome: congenital immune deficiency disease Curr Opin Hematol 16 2009 20 26
37. M. Gleichmann, C. Gillen, M. Czardybon, F. Bosse, R. Greiner-Petter, and J. Auer Cloning and characterization of SDF-1gamma, a novel SDF-1 chemokine transcript with developmentally regulated expression in the nervous system Eur J Neurosci 12 2000 1857 1866 (Pubitemid 30348825)
38. T. Nagasawa, H. Kikutani, and T. Kishimoto Molecular cloning and structure of a pre-B-cell growth-stimulating factor Proc Natl Acad Sci USA 91 1994 2305 2309 (Pubitemid 24092092)
39. T. Nagasawa, K. Tachibana, and T. Kishimoto A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection Semin Immunol 10 1998 179 185 (Pubitemid 28347034)
40. L. Yu, J. Cecil, S.B. Peng, J. Schrementi, S. Kovacevic, and D. Paul Identification and expression of novel isoforms of human stromal cell-derived factor 1 Gene 374 2006 174 179
41. 50) of an enzymatic reaction Biochem Pharmacol 22 1973 3099 3108
42. R. Bertini, M. Allegretti, C. Bizzarri, A. Moriconi, M. Locati, and G. Zampella Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury Proc Natl Acad Sci USA 101 2004 11791 11796 (Pubitemid 39095373)
43. W. Gonsiorek, X. Fan, D. Hesk, J. Fossetta, H. Qiu, and J. Jakway Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist J Pharmacol Exp Ther 322 2007 477 485 (Pubitemid 47105793)
44. C. Watson, S. Jenkinson, W. Kazmierski, and T. Kenakin The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor Mol Pharmacol 67 2005 1268 1282 (Pubitemid 40410427)
45. F. Tsamis, S. Gavrilov, F. Kajumo, C. Seibert, S. Kuhmann, and T. Ketas Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry J Virol 77 2003 5201 5208 (Pubitemid 36460934)
46. T. Dragic, A. Trkola, D.A. Thompson, E.G. Cormier, F.A. Kajumo, and E. Maxwell A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5 Proc Natl Acad Sci USA 97 2000 5639 5644 (Pubitemid 30313771)
47. F.J. Ehlert Analysis of allosterism in functional assays J Pharmacol Exp Ther 315 2005 740 754 (Pubitemid 41500740)
48. L.O. Gerlach, R.T. Skerlj, G.J. Bridger, and T.W. Schwartz Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor J Biol Chem 276 2001 14153 14160
49. M.M. Rosenkilde, L-O. Gerlach, J.S. Jakobsen, R.T. Skerlj, G.J. Bridger, and T.W. Schwartz Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor J Biol Chem 279 2004 3033 3041 (Pubitemid 38114296)
50. A. Brelot, N. Heveker, M. Montes, and M. Alizon Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities J Biol Chem 275 2000 23736 23744 (Pubitemid 30624660)
51. B.J. Doranz, M.J. Orsini, J.D. Turner, T.L. Hoffman, J.F. Berson, and J.A. Hoxie Identification of CXCR4 domains that support coreceptor and chemokine receptor functions J Virol 73 1999 2752 2761 (Pubitemid 29135661)
52. N. Zhou, Z. Luo, J. Luo, D. Liu, J.W. Hall, and R.J. Pomerantz Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies J Biol Chem 276 2001 42826 42833
53. D.J. Chabot, P.F. Zhang, G.V. Quinnan, and C.C. Broder Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates J Virol 73 1999 6598 6609 (Pubitemid 29327842)